...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: aberaterone

That would be a good reason for Zenith to be doing their trial in combo with enzalutamide versus abiraterone. I wonder what the scientists setting up the trial knew when they were designing the trial?

tada

Share
New Message
Please login to post a reply